Targeting oncogenic drivers

Yujie Zhao, Alex Adjei

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Cancer is a genetic disease caused by a series of somatic and/or germline mutations. The roles of oncogenes and tumor suppressors in cancer molecular origin have been well established. Targeting oncogene products has become an attractive therapeutic strategy with great clinical success, whereas tumor suppressors are considered 'undruggable' because current technology is not able to restore tumor suppressor function in metastatic disease. Although systematic approaches to discover genetic alterations have become available to individual patients, differentiating driver from passenger mutations and identifying and validating drug targets remain challenging. Protein tyrosine kinases play crucial roles in virtually all cellular processes and possess structural features that render them 'druggable'. Monoclonal antibodies and small-molecule inhibitors represent two major classes of targeted therapeutic agents, each possessing its own strength and weakness. Although initial successes have been achieved, targeted therapy faces many challenges that need to be addressed and hurdles to overcome.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalProgress in tumor research
Volume41
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Neoplasms
Inborn Genetic Diseases
Germ-Line Mutation
Oncogene Proteins
Oncogenes
Protein-Tyrosine Kinases
Therapeutics
Monoclonal Antibodies
Technology
Mutation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting oncogenic drivers. / Zhao, Yujie; Adjei, Alex.

In: Progress in tumor research, Vol. 41, 01.01.2014, p. 1-14.

Research output: Contribution to journalReview article

Zhao, Yujie ; Adjei, Alex. / Targeting oncogenic drivers. In: Progress in tumor research. 2014 ; Vol. 41. pp. 1-14.
@article{bb6264e3e64e4c979e73423b3b4ccd70,
title = "Targeting oncogenic drivers",
abstract = "Cancer is a genetic disease caused by a series of somatic and/or germline mutations. The roles of oncogenes and tumor suppressors in cancer molecular origin have been well established. Targeting oncogene products has become an attractive therapeutic strategy with great clinical success, whereas tumor suppressors are considered 'undruggable' because current technology is not able to restore tumor suppressor function in metastatic disease. Although systematic approaches to discover genetic alterations have become available to individual patients, differentiating driver from passenger mutations and identifying and validating drug targets remain challenging. Protein tyrosine kinases play crucial roles in virtually all cellular processes and possess structural features that render them 'druggable'. Monoclonal antibodies and small-molecule inhibitors represent two major classes of targeted therapeutic agents, each possessing its own strength and weakness. Although initial successes have been achieved, targeted therapy faces many challenges that need to be addressed and hurdles to overcome.",
author = "Yujie Zhao and Alex Adjei",
year = "2014",
month = "1",
day = "1",
doi = "10.1159/000355895",
language = "English (US)",
volume = "41",
pages = "1--14",
journal = "Progress in tumor research",
issn = "2296-1887",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Targeting oncogenic drivers

AU - Zhao, Yujie

AU - Adjei, Alex

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Cancer is a genetic disease caused by a series of somatic and/or germline mutations. The roles of oncogenes and tumor suppressors in cancer molecular origin have been well established. Targeting oncogene products has become an attractive therapeutic strategy with great clinical success, whereas tumor suppressors are considered 'undruggable' because current technology is not able to restore tumor suppressor function in metastatic disease. Although systematic approaches to discover genetic alterations have become available to individual patients, differentiating driver from passenger mutations and identifying and validating drug targets remain challenging. Protein tyrosine kinases play crucial roles in virtually all cellular processes and possess structural features that render them 'druggable'. Monoclonal antibodies and small-molecule inhibitors represent two major classes of targeted therapeutic agents, each possessing its own strength and weakness. Although initial successes have been achieved, targeted therapy faces many challenges that need to be addressed and hurdles to overcome.

AB - Cancer is a genetic disease caused by a series of somatic and/or germline mutations. The roles of oncogenes and tumor suppressors in cancer molecular origin have been well established. Targeting oncogene products has become an attractive therapeutic strategy with great clinical success, whereas tumor suppressors are considered 'undruggable' because current technology is not able to restore tumor suppressor function in metastatic disease. Although systematic approaches to discover genetic alterations have become available to individual patients, differentiating driver from passenger mutations and identifying and validating drug targets remain challenging. Protein tyrosine kinases play crucial roles in virtually all cellular processes and possess structural features that render them 'druggable'. Monoclonal antibodies and small-molecule inhibitors represent two major classes of targeted therapeutic agents, each possessing its own strength and weakness. Although initial successes have been achieved, targeted therapy faces many challenges that need to be addressed and hurdles to overcome.

UR - http://www.scopus.com/inward/record.url?scp=84927171291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927171291&partnerID=8YFLogxK

U2 - 10.1159/000355895

DO - 10.1159/000355895

M3 - Review article

C2 - 24727983

AN - SCOPUS:84927171291

VL - 41

SP - 1

EP - 14

JO - Progress in tumor research

JF - Progress in tumor research

SN - 2296-1887

ER -